Jeff Yass’s Karuna Therapeutics, Inc. Common Stock KRTX Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2024
Q1 | – | Sell |
-38,118
| Closed | -$12.1M | – | 13733 |
|
|
2023
Q4 | $12.1M | Buy |
38,118
+10,575
| +38% | +$2.06M | ﹤0.01% | 2402 |
|
|
2023
Q3 | $4.66M | Sell |
27,543
-78,240
| -74% | -$14.7M | ﹤0.01% | 3658 |
|
|
2023
Q2 | $22.9M | Buy |
105,783
+60,487
| +134% | +$13M | ﹤0.01% | 1594 |
|
|
2023
Q1 | $8.23M | Buy |
45,296
+30,655
| +209% | +$5.86M | ﹤0.01% | 2731 |
|
|
2022
Q4 | $2.88M | Sell |
14,641
-4,271
| -23% | -$916K | ﹤0.01% | 4084 |
|
|
2022
Q3 | $4.25M | Buy |
18,912
+14,650
| +344% | +$2.97M | ﹤0.01% | 3417 |
|
|
2022
Q2 | $539K | Sell |
4,262
-8,908
| -68% | -$1.02M | ﹤0.01% | 8082 |
|
|
2022
Q1 | $1.67M | Sell |
13,170
-6,863
| -34% | -$773K | ﹤0.01% | 5877 |
|
|
2021
Q4 | $2.62M | Buy |
20,033
+4,223
| +27% | +$546K | ﹤0.01% | 4902 |
|
|
2021
Q3 | $1.93M | Sell |
15,810
-7,473
| -32% | -$863K | ﹤0.01% | 5914 |
|
|
2021
Q2 | $2.65M | Sell |
23,283
-8,047
| -26% | -$941K | ﹤0.01% | 5297 |
|
|
2021
Q1 | $3.77M | Sell |
31,330
-4,853
| -13% | -$550K | ﹤0.01% | 4473 |
|
|
2020
Q4 | $3.68M | Buy |
36,183
+15,923
| +79% | +$1.48M | ﹤0.01% | 3957 |
|
|
2020
Q3 | $1.57M | Sell |
20,260
-1,999
| -9% | -$170K | ﹤0.01% | 5095 |
|
|
2020
Q2 | $2.48M | Buy |
22,259
+7,902
| +55% | +$687K | ﹤0.01% | 4113 |
|
|
2020
Q1 | $1.03M | Buy |
+14,357
| New | +$1.23M | ﹤0.01% | 5331 |
|
Other funds holding KRTX
Jeff Yass's KRTX Position: Q1 2024 in Review
Jeff Yass sold out of Karuna Therapeutics, Inc. Common Stock (KRTX) in Q1 2024, closing a stake of 38,118 shares — an estimated $12.1M sold.
Jeff Yass first reported a position in KRTX in Q1 2020 and held it in 16 quarters. The position peaked at $22.9M in Q2 2023. 2 funds tracked by Wall St. Rank hold KRTX as of Q1 2024.
- Jeff Yass reported no remaining Karuna Therapeutics, Inc. Common Stock position as of Q1 2024 after selling out during the quarter.
- Jeff Yass sold 38,118 Karuna Therapeutics, Inc. Common Stock shares in Q1 2024, an estimated $12.1M.
- Jeff Yass first reported a position in Karuna Therapeutics, Inc. Common Stock in Q1 2020 and held it in 16 quarters.
- Jeff Yass's Karuna Therapeutics, Inc. Common Stock position peaked at $22.9M in Q2 2023.
- 2 funds tracked by Wall St. Rank held Karuna Therapeutics, Inc. Common Stock as of Q1 2024.
Based on Susquehanna International Group's 13F filing for Q1 2024, filed 7 May 2024.